Anest. intenziv. Med. 2009;20(2):84-87
Erythropoietin and other erythropoiesis-stimulating drugs and bloodless medicine - a new era in the management of anaemia?Anaesthesiology - Review articles
- Abteilung für Anästhesie und Intensivmedizin, Landesklinikum Baden, Baden bei Wien, Rakousko
Bloodless medicine tries to find and put into practice alternatives to allogeneic transfusions. The biggest risk when receiving a blood transfusion is the transmission of infectious diseases. Since the 1980s the recombinant human erythropoietin has been used in anaemia treatment, the first of the group of erythropoiesis stimulating agents. Its main disadvantage is the need for frequent applications; a very serious complication - pure red-cell aplasia - occurs rarely.
A second generation drug - darbepoetin - features a modified chemical structure and more favourable pharmacokinetics. A third generation representative of continuous erythropoietin receptor activators will soon be introduced into clinical practice featuring a many times longer biological half-time. The forth generation represents a qualitative leap with oral preparations made up without the help of genetic engineering, starting a new era in anaemia management. However, only the introduction of artificial blood into clinical practice will make blood transfusion a rare procedure.
Keywords: bloodless medicine; erythropoiesis stimulating agents; erythropoietin; darbepoetin; pure red-cell aplasia; continuous erythropoietin receptor activator; Hematide
Received: September 26, 2008; Accepted: January 20, 2008; Published: April 1, 2009 Show citation
References
- Kitchen, A. D., Barbara, J. A. Current information on the infectious risks of allogeneic blood transfusion. Transfusion Alternatives in Transfusion Medicine, 2008, 10, 3, p. 102-111.
Go to original source... - Cundrle, I., Vlach, O., Zimova, I., Pospisilova, M. Initial experience with peroperative autotransfusion in spinal surgery. Acta Chir. Orthop. Traumatol. Cech., 1993, 60, 2, p. 93-97.
Go to PubMed... - Gal, R., Cundrle, I. Acute normovolemic haemodilution for management 4 200 ml large blood loss during radical prostatectomy. Bratisl. Lek. Listy, 2002, 103, 6, p. 198-200.
- Gal, R. Acute normovolemic haemodilution for management of blood loss during radical prostatectomy. Bratisl. Lek. Listy, 2008, 109, 3, p. 144-146. Go to PubMed...
- Segal, J. B., Blasco-Colmenares, E., Norris, E. J., Guallar, E. Preoperative acute normovolemic hemodilution: a meta analysis. Transfusion, 2004, 44, p. 632-644. Go to original source... Go to PubMed...
- Tesař, V., Tesařová, P. Darbepoetin alfa. Farmakoterapie, 2006, 5, p. 514-522.
- Kampf, D., Kahl, A., Passlick, J., Pustelnik, A. et al. Single dose kinetics of recombinant human EPO (rhEPO) after i.v., s.c. and i.p. administration. Control. Nephrol., 1989, 76, p. 106-111.
- Cournoyer, D., Toffelmire, E. B., Wells, G. A., Baeber, D. L. et al. Anti-Erythropoietin Antibody-Mediated Pure Cell Aplasia after Treatment with Recombinant Erythropoietin Products: Recommendations for Minimization of Risk. J. Am. Soc. Nephrol., 2004, 15, p. 2728-2734. Go to original source... Go to PubMed...
- McKoy, J. M., Stonecash, R. E., Cournoyer, D., Rossert, J., Nissenson, A. R., Raisch, D. W. et al. Epoetin-associated pure red cell aplasia: past, present, and future consideration. Transfusion, 2008, 48, 8, p. 1752-1762. Go to original source... Go to PubMed...
- Bennett, C. L., Luminari, S., Nissenson, A., Tallman, M. S. et al. Pure Red-Cell Aplasia and Epoetin Therapy. N. Engl. J. Med., 2004, 351, p. 1403-1408. Go to original source... Go to PubMed...
- Schellekens, H., Jiskoot, W. Erythropoietin-Associated PRCA: Still an Unsolved Mystery. J. Immunot., 2006, 3, p. 123-130. Go to original source... Go to PubMed...
- Chang, W. J., Tan, L. K., Liu, T. C. Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am. J. Kidney Dis., 2003, 41, p. 692-695. Go to original source... Go to PubMed...
- Dostupné na: Amgen Inc. Product Information. http://www.aranesp.com
- Macdougall, I. C., Gray, S. J., Elston, O., Breen, C. et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol., 1999, 10, p. 2392-2395. Go to original source... Go to PubMed...
- Summers, S. A., Matijevic, A., Almond, M. K. Successful re-introduction of recombinant human erythropoietin following antibody induced pure cell aplasia. Nephrol. Dial. Transplant., 2004, 19, p. 2137-2139. Go to original source... Go to PubMed...
- Macdougall, I. C. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for treatment of anemia. Curr. Hematol. rep., 2005, 4, p. 436-440.
- Macdougall, I. C. Novel Erythropoiesis-Stimulating Agents: A New Era in Anemia Management. J. Am. Soc. Nephrol., 2008, 3, p. 200-207. Go to original source... Go to PubMed...
- Stead, R. B., Lamber, J., Wessels, D., Iwashita, J. et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood, 2006, 108, p. 1830-1834. Go to original source... Go to PubMed...